Table 2. Summary of prior chemotherapy.
|
Number of patients
|
Dose intensity | Treatment cycle | ||||
|---|---|---|---|---|---|---|
| Total | CR-PR | SD | PD | Median (range) | Median (range) | |
| Adjuvant | ||||||
| Doxorubicin | 13 | 1.00 (0.82–1.00) | 12 (5–12) | |||
| Taxanes | 6 | 1.00 (0.73–1,00) | 6 (5–9) | |||
| Cisplatin | 2 | NA (0.84, 1.00)a | NA (8, 9)a | |||
| First-line | ||||||
| Taxanes | 19 | 5 | 10 | 4 | 1.00 (0.75–1.00) | 6 (2–9) |
| Cisplatin (±irinotecan) | 5 | 2 | 3 | — | 0.94 (0.56–1.00) | 6 (5–10) |
| Capecitabine | 2 | 2 | — | — | NA (1.00, 0.93)a | NA (7, 9)a |
| Irofulven | 2 | — | 1 | 1 | NA (1.00, 1.00)a | NA (2, 6)a |
| Oxaliplatin | 2 | — | 2 | — | NA (0.98, 0.85)a | NA (8, 10)a |
| Second-line | ||||||
| Taxanes | 7 | 2 | 3 | 2 | 0.93 (0.58–1.00) | 5 (2–9) |
| Cisplatin (±irinotecan) | 3 | — | 1 | 2 | 0.84 (0.49–0.89) | 2 (2–6) |
| Capecitabine | 2 | — | 2 | — | NA (0.94, 0.95)a | NA (4, 9)a |
CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease.
a
Median value was not obtainable due to small patient number (N=2).